➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
AstraZeneca
Medtronic
Harvard Business School

Last Updated: June 2, 2020

DrugPatentWatch Database Preview

LUZU Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

When do Luzu patents expire, and when can generic versions of Luzu launch?

Luzu is a drug marketed by Medicis and is included in one NDA. There are five patents protecting this drug.

This drug has sixty-four patent family members in twenty-five countries.

The generic ingredient in LUZU is luliconazole. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the luliconazole profile page.

US ANDA Litigation and Generic Entry Outlook for Luzu

Luzu was eligible for patent challenges on November 14, 2017.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2034. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Start Trial

Summary for LUZU
International Patents:64
US Patents:5
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Bulk Api Vendors: 46
Patent Applications: 24
Drug Prices: Drug price information for LUZU
DailyMed Link:LUZU at DailyMed
Drug patent expirations by year for LUZU
Drug Prices for LUZU

See drug prices for LUZU

Generic Entry Opportunity Date for LUZU
Generic Entry Date for LUZU*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CREAM;TOPICAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LUZU
Synonyms for LUZU
(-)-(E)-((4R)-4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene)(1H-imidazol-1-yl)acetonitrile
(2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-yl-acetonitrile
(2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile
(R,E)-2-(4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-2-(1H-imidazol-1-yl)acetonitrile
164L198
187164-19-8
1H-Imidazole-1-acetonitrile, alpha-((4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene)-, (alphaE)-
2-[(2E,4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-(1H-imidazol-1-yl)acetonitrile
4-(2,4-Dichlorophenyl)-1,3-dithiolan-2-ylidene-1-imidazolylacetonitrile
A11481
AKOS015897320
AM84645
BCP9000863
C13478
CAS-187164-19-8
CHEBI:34825
CHEMBL2105689
CS-0587
D01980
DB08933
DS-3278
DSSTox_CID_28533
DSSTox_GSID_48607
DSSTox_RID_82805
DTXSID3048607
GTPL7366
HY-14283
Imidazole antimycotic
Lulicon
Lulicon (TN)
Lulicon|||NND 502
Luliconazole
Luliconazole (JAN/USAN/INN)
Luliconazole [USAN:INN]
Luliconazole, >=98% (HPLC)
Luzu (TN)
NCGC00182704-01
NCGC00182704-02
NCGC00182704-03
NND 502
NND-502
NND502
PR-2699
Q15624030
RE91AN4S8G
s4258
SB18987
SCHEMBL342362
SR-01000945039
SR-01000945039-1
SW219226-1
Tox21_112942
Tox21_112974
Tox21_112974_1
UNII-5JA16R08FJ component YTAOBBFIOAEMLL-REQDGWNSSA-N
UNII-RE91AN4S8G
W-5249
ZINC3929486

US Patents and Regulatory Information for LUZU

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Medicis LUZU luliconazole CREAM;TOPICAL 204153-001 Nov 14, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Medicis LUZU luliconazole CREAM;TOPICAL 204153-001 Nov 14, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Medicis LUZU luliconazole CREAM;TOPICAL 204153-001 Nov 14, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Medicis LUZU luliconazole CREAM;TOPICAL 204153-001 Nov 14, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Medicis LUZU luliconazole CREAM;TOPICAL 204153-001 Nov 14, 2013 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Colorcon
AstraZeneca
Medtronic
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.